| 人提供个性化的健康管理方案和生活服务。公司也积极与各类科技公 | | --- | | 司合作，推动智慧养老生态圈的建设。 | | 3、公司养老院运营模式？公司目前运营的养老机构情况？ | | 答：公司目前康养业务主要采用轻资产运营模式，以托管运营公 | | 建民营项目为主。已经落地运营的项目有上海奉贤金海悦心颐养院、 | | 江苏宿迁的悦心·泗洪康养中心、浙江温州龙港市医养康教研示范园。 | | 此外，也通过外延并购扩张规模，采用直接战略参股及设立投资孵化 | | 平台为公司储备和培育新的战略项目，目前已战略投资了浙江康芮嘉 | | 养健康管理有限公司等项目。 | | 4、大健康营业收入规模？ | | 答：2024 年，公司大健康业务营业收入 1.08 亿元，收入构成主 | | 要为医疗服务收入、养老服务收入及职业教育收入。 | | 5、公司有没有养老机器人方面的计划？ | | 答：公司计划通过技术创新和合作，进一步拓展智慧养老场景。 | | 公司运用智能化设备更偏向于养老场景的服务应用端，通过科技手段 | | 增强服务品质，降低管理成本。 | | 6、公司未来的扩张计划？ | | 答：在大健康领域，公司 ...

Core Viewpoint - The article highlights the recent trend of foreign investment in China's industrial manufacturing sector, indicating a renewed focus on investment opportunities as companies announce share buybacks and foreign institutions increase their holdings in potential stocks [1][2]. Group 1: Foreign Investment Activities - Several prominent foreign institutions have recently increased their stakes in potential stocks within the industrial manufacturing sector, signaling confidence in the recovery of China's manufacturing industry [2]. - The Singapore Government Investment Corporation (GIC) has increased its holdings in Huaming Equipment, while Barclays and Goldman Sachs have raised their stakes in Yueshin Health [2][5]. - Morgan Stanley has also increased its investment in Weiman Sealing, reflecting a broader trend of foreign capital re-engaging with the Chinese market [2][7]. Group 2: Company-Specific Insights - **Huaming Equipment**: GIC now holds 18.08 million shares, representing 2.02% of the total share capital. The company is recognized for its comprehensive production capabilities in transformer tap changers and has a significant market share in China [3][4]. - **Yueshin Health**: Barclays and Goldman Sachs have increased their holdings by 2.25 million shares combined, focusing on health and wellness services, as well as smart healthcare solutions [5][6]. - **Weiman Sealing**: Morgan Stanley holds 370,000 shares, accounting for 0.31% of the total share capital. The company specializes in hydraulic and pneumatic sealing products and is working on high-end material development to enhance its market position [8].

证券代码：002162 证券简称：悦心健康 公告编号：2025-026 上海悦心健康集团股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 一、股票交易异常波动的情况介绍 公司目前康养服务业务主要为托管运营公建民营养老机构，为入住长者提供生 活照料与医疗护理服务，在运营过程中，公司利用智能化设备、系统和远程医疗功 能提升养老机构的运营效率和服务质量。2024年，公司成立了全资子公司上海悦心 多宝智能科技有限公司，专注于养老机构智能化管理系统的开发与应用、智慧养老 产品的应用研究，并计划通过技术创新和合作，进一步拓展智慧养老场景，包括且 不限于引入或开发养老和辅助机器人、优化智慧养老产品等，以满足长者多样化的 需求。上海悦心多宝智能科技有限公司虽在技术积累和养老服务创新方面有一定布 局，但目前仍处于技术研发和积累阶段。上海悦心多宝智能科技有限公司2024年度 营业收入为4.95万元，占比极小，尚未形成规模化销售，短期不会对公司经营业绩 产生重大影响。敬请广大投资者关注风险，理性判断投资价值。 （三）重大事项情况 上海悦心健康集 ...

| | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 √业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 （请文字说明其他活动内容） | | 活动参与人员 | 参与公司 2024 年度业绩说明会的投资者 | | 时间 2025 | 年 3 月 6 日 15:00-17:00 | | 地点 | 全景网投资者关系互动平台（http://ir.p5w.net） | | | 董事长兼总裁 李慈雄 | | 上市公司 | 执行副总裁 何志明 | | | 财务负责人 赵一非 | | 接待人员 | 董事会秘书 程 梅 | | | 独立董事 阮永平 | | 形式 | 网上业绩说明会 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、请问公司对最近比较火的机器人和康养的结合发展上，有规划 | | | 么？ | | | 答：你好！公司计划在智能医疗和养老系统中应用机器人技术。 | | | 尝试利用 AI 算法和智能穿戴设备进行健康监测和数据分析，并通过 | | 交流内容及 ...

证券代码：002162 证券简称：悦心健康 公告编号：2025-025 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 关于回购股份事项前十名股东和前十名无限售条件股东 持股情况的公告 上海悦心健康集团股份有限公司（以下简称"公司"）于2025年2月26日召开第 八届董事会第十三次会议，审议通过了《关于回购公司股份方案的议案》，具体内 容详见公司于2025年2月28日披露在《中国证券报》、《证券时报》、《上海证券报》、 《证券日报》和巨潮资讯网（www.cninfo.com.cn）上的《第八届董事会第十三次会 议决议公告》（公告编号：2025-007）、《关于回购公司股份方案的公告》（公告编 号：2025-017）。 根据《深圳证券交易所上市公司自律监管指引第9号——回购股份》（2023年修 订）相关规定，现将公司董事会公告回购股份决议的前一个交易日（即2025年2月27 日）登记在册的前十名股东和前十名无限售条件股东的名称及持股数量、比例情况 公告如下： | 序号 | 股东名称 | 持股数量（股） | 占总股本比例（%） | | --- | --- | ...

Financial Performance - The company reported a total revenue of RMB 921,584,303 for the year 2024, with no cash dividends or stock bonuses distributed to shareholders [4]. - The company's operating revenue for 2024 was ¥1,204,147,736.16, a decrease of 5.79% compared to ¥1,278,144,047 in 2023 [21]. - The net profit attributable to shareholders for 2024 was -¥147,124,591.55, representing a decline of 393.87% from a profit of ¥50,063,818.15 in 2023 [21]. - The net profit after deducting non-recurring gains and losses was -¥167,586,639.58, a 42.12% increase in loss compared to -¥117,920,636.43 in 2023 [21]. - The net cash flow from operating activities decreased by 33.48% to ¥82,229,306.63 from ¥123,616,172.02 in 2023 [21]. - The total assets at the end of 2024 were ¥2,057,924,527.48, down 12.76% from ¥2,358,838,216.90 at the end of 2023 [21]. - The net assets attributable to shareholders decreased by 16.72% to ¥826,496,223.46 from ¥992,468,338.54 at the end of 2023 [21]. - The company reported a significant uncertainty regarding its ability to continue as a going concern, as indicated in the audit report [22]. - The company reported a net loss of RMB 147,124,591.55 for the consolidated financial statements in 2024, with the parent company reporting a net loss of RMB 542,266,812.44 [145]. Business Strategy and Outlook - Future outlook indicates a focus on expanding health management consulting services and technology development in the medical field [4]. - The company plans to enhance its product offerings in precision ceramics and health management consulting, aligning with market trends [20]. - No acquisitions or mergers were mentioned in the report, indicating a potential focus on organic growth strategies [4]. - The company aims to enhance its core competitiveness in the building materials sector by focusing on market-oriented product development and digital marketing strategies [98]. - The company plans to expand its health and wellness services, targeting the integration of medical and elderly care services, and aims to enhance its core competitiveness through digital transformation [101]. - The company will implement a dual-brand strategy, with "Simic" for building materials and "Yuexin" for health services, focusing on a five-in-one model of medical care, health, education, and research [103]. Market and Industry Trends - The company’s building materials business focuses on high-end ceramic brand "Simik," with a diverse product range including glazed tiles and artistic ceramics [40]. - The industry’s actual production in 2024 is expected to be 5.2 billion square meters, a 23% decline year-on-year [32]. - The retail sales of building and decoration materials in China decreased by 2% year-on-year, while the total retail sales of social consumer goods grew by 3.5% to CNY 487,895 billion [39]. - The company anticipates that the building ceramics industry will continue to evolve towards sustainability and smart manufacturing, driven by consumer demand and regulatory policies [92]. Governance and Compliance - The company emphasizes compliance with regulatory requirements for its business operations, particularly in health-related services [20]. - The governance structure of the company is in compliance with relevant regulations and does not have unresolved governance issues [109]. - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, and business operations [110]. - The company has established a commitment to provide financial support for a period of 12 months to assist in resolving short-term liquidity issues [181]. Environmental Management - The company has a valid pollution discharge permit effective until October 16, 2027, ensuring compliance with environmental regulations [162]. - The company’s environmental management practices include strict control over pollutant emissions to meet industry standards [161]. - Jiangxi Smick's environmental protection investment for 2024 amounted to 3.1924 million yuan, with an environmental protection tax payment of 38,000 yuan [170]. - Jiangxi Smick has implemented an online monitoring system for emissions, which is connected to various environmental protection platforms for real-time data tracking [169]. Human Resources and Talent Development - The total number of employees at the end of the reporting period is 803, with 590 in the parent company and 213 in major subsidiaries [137]. - The company conducted a total of 162 training sessions in 2024, enhancing employee skills and supporting distributors [140]. - The company emphasizes performance management and has established a comprehensive performance management system to motivate employees [139]. - The company has a dedicated human resources department that operates independently from the controlling shareholder [110]. Shareholder and Executive Changes - The company experienced a change in executive leadership, with the resignation of the president, Yu Jing, effective December 31, 2024 [114]. - The company appointed Wang Qixin and Ye Kuangshi as independent directors on June 7, 2024, to fill vacancies [114]. - The company’s board composition reflects a mix of experienced professionals from various industries, which may contribute to its growth strategy [115][116][117][118]. Research and Development - Research and development expenses decreased by 22.43% to ¥7,918,208.12 compared to the previous year [74]. - The number of R&D personnel decreased by 29.22% to 109, with the proportion of R&D personnel in the total workforce dropping to 13.57% [78]. - Total R&D investment was ¥28,272,245.30, a decrease of 6.02% from the previous year, while the ratio of R&D investment to operating income remained stable at 2.35% [79]. Financial Commitments and Transactions - The company has established a comprehensive performance evaluation and incentive mechanism for senior management, linking their interests with those of shareholders [152]. - The company granted 970,000 stock options to 53 incentive targets at an exercise price of RMB 3.41 per share as part of the 2023 stock option incentive plan [147]. - The company has no non-operating fund occupation by controlling shareholders or related parties during the reporting period [184]. - The company has fulfilled all commitments related to avoiding competition and regulating related transactions as of the reporting period [180].

证券代码：002162 证券简称：悦心健康 公告编号：2025-017 上海悦心健康集团股份有限公司 关于回购公司股份方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 重要内容提示： 1、拟回购股份基本情况 （1）拟回购资金总额：不低于人民币600万元（含），不超过人民币1,000万元（含）； （2）拟回购股份的种类：公司已发行的人民币普通股（A股）股票； （5）拟回购数量：按照回购金额上限、回购价格上限测算，预计可回购股份数量约 为200万股，约占公司当前总股本的0.22%；按回购金额下限、回购价格上限测算，预计可 回购股份数量约为120万股，约占公司当前总股本的0.13%。具体回购股份数量以回购期限 届满时实际回购的股份数量为准； （6）实施期限：自股东大会审议通过本次回购方案之日起12个月内； （7）资金来源：公司自有资金或自筹资金。 如国家对相关政策作调整，则本回购方案按调整后的政策实行。 2、相关股东是否存在减持计划 截至本公告日，公司董事、监事、高级管理人员、控股股东及其一致行动人目前暂 无明确的减持公司股份计划，如后续新增减持股份计 ...

上海悦心健康集团股份有限公司 2024 年度 非经营性资金占用及其他关联资金往来的 专项说明 索引 页码 专项说明 非经营性资金占用及其他关联资金往来情况汇总表 1-2 关于上海悦心健康集团股份有限公司 2024 年度非经营性资金占用及其他关联资金往来的专项说明 XYZH/2025SHAA2B0007 上海悦心健康集团股份有限公司 XYZH/2025SHAA2B0007 上海悦心健康集团股份有限公司 本专项说明仅供悦心健康集团 2024 年度报告披露之目的使用，未经本事务所书面同 意，不得用于其他任何目的。 上海悦心健康集团股份有限公司全体股东： 我们按照中国注册会计师审计准则审计了上海悦心健康集团股份有限公司（以下简称 悦心健康集团）2024 年度财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表、 2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司股东权益变 动表以及财务报表附注，并于 2025 年 2 月 26 日出具了 XYZH/2025SHAA2B0010 号无保留意 见的审计报告。 根据中国证券监督管理委员会《上市公司监管指引第 8 号——上市公司资金往 ...

按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了 上海悦心健康集团股份有限公司（以下简称 悦心健康集团）2024 年 12 月 31 日财务报告 内部控制的有效性。 一、 企业对内部控制的责任 按照《企业内部控制基本规范》 、《企业内部控制应用指引》 、《企业内部控制评价 指引》的规定，建立健全和有效实施内部控制，并评价其有效性是悦心健康集团董事会的 责任。 上海悦心健康集团股份有限公司 2024 年度 内部控制审计报告 内部控制审计报告 XYZH/2025SHAA2B0009 上海悦心健康集团股份有限公司 上海悦心健康集团股份有限公司全体股东： 二、 注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意 见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、 内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的变 化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制审 计结果推测未来内部控制的有效性具有一定风险。 四、 财务报告内部控制审计意见 我们认为，悦心健康集团于 2 ...

上海悦心健康集团股份有限公司 2024 年度 审计报告 | 索引 | | 页码 | | --- | --- | --- | | 审计报告 | | | | 公司财务报告 | | | | — | 合并资产负债表 | 1-2 | | — | 母公司资产负债表 | 3-4 | | — | 合并利润表 | 5 | | — | 母公司利润表 | 6 | | — | 合并现金流量表 | 7 | | — | 母公司现金流量表 | 8 | | — | 合并股东权益变动表 | 9-10 | | — | 母公司股东权益变动表 | 11-12 | | — | 财务报表附注 | 13-120 | 审计报告 XYZH/2025SHAA2B0010 上海悦心健康集团股份有限公司 上海悦心健康集团股份有限公司全体股东： 一、 审计意见 我们审计了上海悦心健康集团股份有限公司（以下简称 悦心健康集团）财务报表， 包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、 合并及母公司现金流量表、合并及母公司股东权益变动表，以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的 ...